AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of ...

Gasdermin C activation boosts type II immunity against helminths, and NSAIDs may someday offer a novel, repurposed treatment ...

Three applications for gene editing in conservation are restoring lost variation and facilitated adaptation as well as reducing harmful mutations.

Sarepta Therapeutics said it will voluntarily “and temporarily” pause all shipments of Elevidys® (delandistrogene ...

Biogen said it intends to invest an additional $2 billion to expand operations at its largest manufacturing facilities within North Carolina’s Research Triangle Park (RTP).

VISTA, an AI-controlled data loop system, guides large-scale antibody design from scratch for applications in cancer therapy.

Prime editing corrects the most common genetic mutations that cause alternating hemiplegia of childhood (AHC), a rare and ...

IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and ...

Highlights of the Sanner facility include a 60,500-sq-ft site equipped with GMP-certified cleanrooms (ISO class 7 & 8) and ...

Using data from the T2T reference, scientists linked two new genes to changes in brain size and synapse signaling.

Study harnesses a cell-type-specific, multi-target drug discovery strategy grounded in human data and real-world evidence.

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...